AstraZeneca PLC Director/PDMR Shareholding (7348P)

TIDMAZN

RNS Number : 7348P

AstraZeneca PLC

13 February 2023

13 February 2023 14:01 GMT

Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announced that, on 9 February 2023, an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the AstraZeneca Investment Plan (AZIP) vested to Pascal Soriot, Executive Director and Chief Executive Officer.

The AZIP award was granted on 27 March 2015 and was subject to a four-year performance period followed by a four-year holding period before vesting. Application of the performance measures specified at the time of grant resulted in 75% of the AZIP award entering the holding period.

Following the reinvestment of dividends accrued during the performance and holding periods and the withholding of shares to satisfy certain tax obligations arising on vesting, Mr Soriot acquired Ordinary Shares as detailed in the table below:

 
 PDMR                 Ordinary Shares 
                   acquired under the 
                                 AZIP 
 Pascal Soriot                 15,187 
                 --------------------

For tax purposes, the fair market value of an Ordinary Share at vest was 10,752 pence, being the closing price on the last trading day preceding the vesting.

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (since it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

 
       Details of the person discharging managerial responsibilities 
  1     / person closely associated 
 a)    Name                        Pascal Soriot 
      --------------------------  ----------------------------------------- 
       Reason for the notification 
  2 
      --------------------------------------------------------------------- 
 a)    Position/status             Chief Executive Officer 
      --------------------------  ----------------------------------------- 
 b)    Initial notification        Initial notification 
        /Amendment 
      --------------------------  ----------------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------- 
 a)    Name                        AstraZeneca PLC 
      --------------------------  ----------------------------------------- 
 b)    LEI                         PY6ZZQWO2IZFZC3IOL08 
      --------------------------  ----------------------------------------- 
       Details of the transaction(s): section to be repeated 
  4i    for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      --------------------------------------------------------------------- 
 a)    Description of the          Ordinary Shares of US$0.25 each in 
        financial instrument,       AstraZeneca PLC 
        type of instrument 
 
        Identification code         GB0009895292 
      --------------------------  ----------------------------------------- 
 b)    Nature of the transaction   Acquisition of Ordinary Shares pursuant 
                                    to a vesting under the AstraZeneca 
                                    Investment Plan, for nil consideration. 
      --------------------------  ----------------------------------------- 
 c)    Price(s) and volume(s)        Price(s)   Volume(s) 
                                      0          15,187 
                                                ---------- 
      --------------------------  ----------------------------------------- 
 d)    Aggregated information      Not applicable - single transaction 
 
        - Aggregated volume 
        - Price 
      --------------------------  ----------------------------------------- 
 e)    Date of the transaction     9 February 2023 
      --------------------------  ----------------------------------------- 
 f)    Place of the transaction    Outside a trading venue 
      --------------------------  -----------------------------------------

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca .

Contacts

For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHUORAROUUUAAR

(END) Dow Jones Newswires

February 13, 2023 09:01 ET (14:01 GMT)

Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024